Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 744-750

  Uehara, Takashi ^a   Mitsuhashi, Akira ^a   Tsuruoka, Nobuhide ^a   Shozu, Makio ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Combination treatment; Endometrial cancer; Hypoxia; Metformin

Indexed keywords

CISPLATIN; METFORMIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL HYPOXIA; CELL SIZE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOMETRIAL CANCER CELL LINE; IN VITRO STUDY; MITOCHONDRION; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IN VITRO TECHNIQUES; METFORMIN; MITOCHONDRIA;

EID: 84919443825     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3611     Document Type: Article

References (41)

1. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
2. Decensi A, Puntoni M, Goodwin P, et al: Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3: 1451-1461, 2010.
3. Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7: e33411, 2012.
4. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064, 2010.
5. Quinn BJ, Kitagawa H, Memmott RM, et al: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24: 469-480, 2013.
6. Hanna RK, Zhou C, Malloy KM, et al: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 125: 458-469, 2012.
7. Dong L, Zhou Q, Zhang Z, et al: Metformin sensitizes endo-metrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res 38: 1077-1085, 2012.
8. Shank JJ, Yang K, Ghannam J, et al: Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 127: 390-397, 2012.
9. Liu H, Scholz C, Zang C, et al: Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32: 1627-1637, 2012.
10. Ashinuma H, Takiguchi Y, Kitazono S, et al: Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep 28: 8-14, 2012.
11. Rattan R, Graham RP, Maguire JL, et al: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
12. Kim HG, Hien TT, Han EH, et al: Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE tran-scriptional activity through AMPK activation. Br J Pharmacol 162: 1096-1108, 2011.
13. Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifes chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005, 2011.
14. Nilsson S, Huelsenbeck J and Fritz G: MevaloNate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer Lett 304: 60-69, 2011.
15. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71: 3196-3201, 2011.
16. Janjetovic K, Vucicevic L, Misirkic M, et al: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 651: 41-50, 2011.
17. Yasmeen A, Beauchamp MC, Piura E, et al: Induction of Apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 121: 492-498, 2011.
18. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, et al: AMPK-mediated autophagy inhibits Apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 13: 3644-3654, 2009.
19. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
20. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
21. Graham GG, Punt J, Arora M, et al: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50: 81-98, 2011.
22. Lalau JD, Lacroix C, Compagnon P, et al: Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18: 779-784, 1995.
23. Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2: 344-355, 2012.
24. Berridge MV, Herst PM and Tan AS: Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152, 2005.
25. Ishiyama M, Miyazono Y, Sasamoto K, et al: A highly water-soluble disulfoNated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997.
26. Collier AC and Pritsos CA: The mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem Pharmacol 66: 281-287, 2003.
27. Pagliacci MC, Spinozzi F, Migliorati G, et al: Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 29A: 1573-1577, 1993.
28. Burzawa JK, Schmeler KM, Soliman PT, et al: Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204: 355.e1-7, 2011.
29. Soliman PT, Wu D, Tortolero-Luna G, et al: Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106: 2376-2381, 2006.
30. Mu N, Zhu Y, Wang Y, et al: Insulin resistance: a signifcant risk factor of endometrial cancer. Gynecol Oncol 125: 751-757, 2012.
31. Johnson N, Bryant A, Miles T, et al: Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 10: CD003175, 2011.
32. Vale CL, Tierney J, Bull SJ and Symonds PR: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 8: CD003915, 2012.
33. El-Mir M Y, Nogueira V, Fontaine E, et al: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228, 2000.
34. Owen MR, Doran E and Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614, 2000.
35. Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24: 49-57, 1994.
36. Cantrell LF, Nelson CL, Gary RD and McIntyre IM: Fatal metformin intoxication with markedly elevated Blood and liver concentrations. J Anal Toxicol 36: 657-659, 2012.
37. Sanchez-Alvarez R, Martinez-Outschoorn UE, Lamb R, et al: Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. Cell Cycle 12: 172-182, 2013.
38. Poot M, Zhang YZ, Krämer JA, et al: Analysis of mitochondrial morphology and function with novel fxable fuorescent stains. J Histochem Cytochem 44: 1363-1372, 1996.
39. Renehan AG, Tyson M, Egger M, et al: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569-578, 2008.
40. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
41. Goodwin PJ, Pritchard KI, Ennis M, et al: Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8: 501-505, 2008.